9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio
PierFranco Conte(University of Padua), Roberto D’Amico(University of Modena and Reggio Emilia), Ornella Garrone(Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo), Anita Rimanti(Azienda Ospedaliera Carlo Poma), Samanta Sarti(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Valentina Guarneri(Istituto Oncologico Veneto), Sara Balduzzi(Dutch Cancer Society), Giancarlo Bisagni, C. Taverniti(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Roberto Vicini, Antonino Musolino(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Luigi Cavanna(University of Pavia), Francesco Giotta(Istituto Tumori Bari), Alba A. Brandes(Istituto delle Scienze Neurologiche di Bologna), Federico Piacentini(Azienda Unita' Sanitaria Locale Di Modena), Vittorio Gebbia(La Maddalena), Alessandra Bologna(Azienda Sanitaria Unità Locale di Reggio Emilia), Daniela Rubino(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Michele Aieta(Centro di Riferimento Oncologico della Basilicata)
Cited by 6
Related Papers
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|IRIS UNIMORE (University of Modena and Reggio Emilia)|2005|1.6k
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
|JAMA Oncology|2019|1k
Lomustine and Bevacizumab in Progressive Glioblastoma
|New England Journal of Medicine|2017|994
Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations
|New England Journal of Medicine|2020|879